COVID-19: FDA’s Stenzel Talks Abbott Test, Future Clearances In Call
Timothy Stenzel, director of the Office of In Vitro Diagnostics and Radiological Health within the US agency's device center, offered an update on a controversial Abbott test and covered other issues during a COVID-19 developer webinar.
You may also be interested in...
Abbott’s medical device sales were down about 20% year-over-year in the second quarter of 2020, but diagnostics sales were up 7%. Procedure trends at the end of the second quarter suggest that demand for devices will soon recover to pre-pandemic levels.
Manufacturers faced with an increasingly complex landscape of state patient-privacy laws may opt to comply with federal Health Insurance Portability and Accountability Act regulations instead, attorney Brad Rostolsky tells Medtech Insight.
The special controls are to include biocompatibility, sterility and performance testing, as well as physician training and warning labels.